Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
81.14
-2.22 (-2.66%)
At close: Aug 13, 2025, 4:00 PM
81.97
+0.83 (1.02%)
After-hours: Aug 13, 2025, 5:26 PM EDT
Soleno Therapeutics Employees
Soleno Therapeutics had 92 employees as of December 31, 2024. The number of employees increased by 59 or 178.79% compared to the previous year.
Employees
92
Change (1Y)
59
Growth (1Y)
178.79%
Revenue / Employee
$354,967
Profits / Employee
-$1,968,250
Market Cap
4.31B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SLNO News
- 6 days ago - Soleno Therapeutics, Inc. (SLNO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 - GlobeNewsWire
- 7 weeks ago - Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome - GlobeNewsWire
- 3 months ago - Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome - GlobeNewsWire